RESULTS – HEMOPHILIA

RESULTS

  • Biogen rapidly gained positive exposure to the hemophilia community demonstrating corporate leadership in a disease state that is difficult to break into.
  • Biogen built trust in a skeptical patient community by identifying itself as a partner providing a solution to an unmet medical need
  • MLOF provided an opportunity to establish a data set that researchers could tap into further R&D for better treatments for bleeding disorders.
  • Beyond building trust and demonstrating leadership, this advocacy initiative resulted in intimate and trustworthy relationships with HCP KOLs and patient leaders within hemophilia – an asset during the commercial launch of the 2 approved products for patients with hemophilia.